Steritas Partners with argenx for Steroid Toxicity Research

Steritas LLC has entered into a licensing agreement with argenx to integrate its STOX® Suite of steroid-toxicity clinical outcome assessments (COAs) into argenx’s immunology research. The suite provides a standardized, digital method for assessing steroid-related harm, which can help in optimizing treatments and improving patient care. As part of the collaboration, argenx will use the STOX Suite in clinical trials and real-world research to investigate chronic steroid usage and its impact on autoimmune disease treatments. This agreement underscores the importance of addressing steroid-related toxicity in modern healthcare.

The collaboration is a significant step in enhancing the understanding of long-term steroid use, which remains prevalent despite the availability of newer therapies. By focusing on the harmful effects of steroids, the partnership aims to foster the development of steroid-sparing treatments. Steritas' CEO, Martha Stone, emphasized that addressing steroid toxicity is vital not only for autoimmune diseases but also for other chronic conditions where steroids are a primary treatment.

This agreement is expected to produce valuable data that could inform therapeutic strategies, reduce the burden of steroid use, and improve patient outcomes. According to Luc Truyen, M.D., Ph.D., Chief Medical Officer of argenx, the collaboration will help the company better understand the real-world impact of steroid use, ensuring their medicines address both the disease burden and the side effects of current treatments.